Related Experiment Video
Updated: Apr 20, 2026

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
Epigenetic inhibitors
Mukesh Verma1, Hirendra Nath Banerjee
1Methods and Technologies Branch, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD, 20852, USA.
Abstract:
Traditional treatments for cancer include chemotherapy, radiation therapy, and surgery. Recently, epigenetic inhibitors have been found to be very effective in cancer treatment. Epigenetic changes such as DNA methylation, histone deacetylation, and microRNA (miRNA) expression are capable of silencing the expression of tumor suppressor genes and inducing oncogenes, leading to clonal proliferation of tumor cells. Methyltransferase inhibitors and histone deacetylase inhibitors have attracted the attention of researchers and clinicians because they provide an alternative therapeutic regime in some diseases, including cancer.Epigenetic changes are characterized by altered gene expression without any changes in the nucleotide sequences of DNA. In addition, epigenetic changes are dynamic and can be reversed by epigenetic inhibitors. Drugs that inhibit DNA methylation or histone deacetylation have been studied for the reactivation of tumor suppressor genes and repression of cancer cell growth. Epigenetic inhibitors work alone or in combination with other therapeutic agents. To date, several epigenetic inhibitors have been approved for cancer treatment. The main challenge in the field of epigenetic inhibitors is their lack of specificity. Their mechanisms of action and potential in treating cancer are described in this article.
Insights
Epigenetic inhibitors offer a novel approach to cancer treatment by reversing gene expression changes without altering DNA sequences. These drugs show promise in reactivating tumor suppressor genes and inhibiting cancer cell growth.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer involves epigenetic changes like DNA methylation and histone deacetylation, which can silence tumor suppressor genes.
- Epigenetic modifications are dynamic and reversible, offering therapeutic targets.
- Traditional cancer treatments include chemotherapy, radiation, and surgery.
Purpose of the Study:
- To explore the mechanisms and therapeutic potential of epigenetic inhibitors in cancer treatment.
- To review approved epigenetic inhibitors and their applications.
- To identify challenges in the field, such as lack of specificity.
Main Methods:
- Review of scientific literature on epigenetic inhibitors and cancer.
- Analysis of mechanisms of action for DNA methylation and histone deacetylase inhibitors.
- Discussion of clinical applications and approved drugs.
Main Results:
- Epigenetic inhibitors can reverse aberrant gene expression linked to cancer.
- Drugs targeting DNA methylation and histone deacetylation show efficacy in preclinical and clinical studies.
- Several epigenetic inhibitors are approved for cancer therapy, often used in combination treatments.
Conclusions:
- Epigenetic inhibitors represent a promising therapeutic strategy for cancer.
- Reactivation of tumor suppressor genes and repression of cancer cell growth are key outcomes.
- Improving the specificity of epigenetic inhibitors remains a critical challenge for future development.
More Related Videos
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Epigenetic Regulation
Inhibitors of Bacterial DNA Synthesis
Enzyme Inhibition

